Journal
STRUCTURE
Volume 24, Issue 10, Pages 1719-1728Publisher
CELL PRESS
DOI: 10.1016/j.str.2016.06.026
Keywords
-
Funding
- Burroughs Welcome Fund
- NVIDIA Corporation
- NIH [1DP5OD021345]
Ask authors/readers for more resources
The immune checkpoint receptor PD-1 and its ligand, PD-L1, have emerged as key regulators of antitumor immunity in humans. Recently, we reported an ultra-high-affinity PD-1 mutant, termed high-affinity consensus (HAC) PD-1, which shows superior therapeutic efficacy in mice compared with antibodies. However, the molecular details underlying the action of this agent remain incompletely understood, and a molecular view of PD-1/PD-L1 interactions in general is only beginning to emerge. Here, we report the structure of HAC PD-1 in complex with PD-L1, showing that it binds PD-L1 using a unique set of polar interactions. Biophysical studies and long-timescale molecular dynamics experiments reveal the mechanisms by which ten point mutations confer a 35,000-fold enhancement in binding affinity, and offer atomic-scale views of the role of conformational dynamics in PD-1/PD-L1 interactions. Finally, we show that the HAC PD-1 exhibits pH-dependent affinity, with pseudo-irreversible binding in a low pH setting akin to the tumor microenvironment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available